LYN-00101 / Lynkcell - LARVOL DELTA

Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: Lynkcell Inc.; N=19 ➔ 0; Trial completion date: Feb 2020 ➔ Aug 2020; Active, not recruiting ➔ Withdrawn; Trial primary completion date: Nov 2019 ➔ Jun 2020

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial withdrawal • CRP • MRI